Isofol Medical AB (publ) (STO: ISOFOL)

Market Cap	468.39M
Revenue (ttm)	-1.00K
Net Income (ttm)	-34.70M
Shares Out	161.52M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,672,980
Open	3.200
Previous Close	3.190
Day's Range	2.865 - 3.370
52-Week Range	0.450 - 4.885
Beta	2.05
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About Isofol Medical AB

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 4
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ISOFOL

Financial Performance

In 2023, BOTX's revenue was 213,000, a decrease of -90.28% compared to the previous year's 2.19 million. Losses were -7.28 million, -4.11% less than in 2022.